QC
LTRN icon

Quadrature Capital’s Lantern Pharma LTRN Stock Holding History

Quadrature Capital’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Buy
+39,593
New +$116K ﹤0.01% 1390

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Quadrature Capital's LTRN Position: Q2 2026 in Review

Quadrature Capital opened a new position in Lantern Pharma (LTRN) in Q2 2026: 39,593 shares worth $165K. The stake represents ﹤0.01% of the portfolio and ranks #1390 among its holdings.

17 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Quadrature Capital held 39,593 shares of Lantern Pharma worth $165K as of Q2 2026.
  • Lantern Pharma was a new Quadrature Capital position in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1390 holding.
  • 17 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.